Etanercept Biosimilar Insight Market Report 2024: Pipeline Analysis, Therapeutic Assessment, Sales Assessment, Unmet Needs, and Impact of Drugs
September 19, 2024 10:21 ET
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Etanercept - Biosimilar Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This "Etanercept - Biosimilar Insight, 2024" report...
Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi
August 23, 2024 07:20 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
US Biosimilar Market Research 2024-2028 Featuring Leading Players - Pfizer, Novartis, Amgen, Samsung Biologics, Celltrion, and Viatris
August 12, 2024 05:28 ET
|
Research and Markets
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "US Biosimilar Market: Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.The US biosimilar market is...
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
July 11, 2024 08:00 ET
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
Biosimilars Training Course (2-Days Online: October 1-2, 2024) - Global Considerations and Strategies for Biotech/Biosimilar Products and Regulatory Pathways in EU and US
July 03, 2024 11:25 ET
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
July 01, 2024 02:03 ET
|
Samsung Bioepis
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
June 25, 2024 09:00 ET
|
Samsung Bioepis
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
Biosimilars Training Course: Prepare for Growth as Some of the World's Best-known Biologics Face Patent Expiration in the Coming Years (ONLINE EVENT)
June 20, 2024 04:55 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
June 14, 2024 03:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
Global Biosimilar Contract Manufacturing Market Forecast 2024-2034 | A Projected $48.67 Billion Opportunity with Profiles of 10+ Leading Market Players | Oncology Applications in North America Dominate
June 05, 2024 03:36 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The...